As a human hematopoietic CSC marker, Walter et al. proposed that upregulated CD133 in ERMS can act as a prognostic marker and might help with the development of novel targeted therapies for ERMS [38]. Here, PROM1 is linked to embryonal rhabdomyosarcoma.